Advicenne SA

ADVICENNE S.A. has a market capitalization of $18.04 million and a market price of $1.27 per share, with 14.16 million shares outstanding. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's operating cash flow is negative at -$3.73 million, indicating a reliance on external financing or asset sales to fund operations. The company's profitability metrics are not available due to the lack of comprehensive financial data. However, the absence of positive operating cash flow suggests that the company is not yet generating sufficient revenue to cover its operating expenses. The company's revenue for the latest period is $5.79 million, which is relatively low for a biopharmaceutical company in the late-stage development phase. ADVICENNE S.A. does not disclose segment or geographic revenue breakdowns in the provided data, making it difficult to assess revenue concentration or geographic exposure. The company's focus on orphan renal diseases and niche neurology indications suggests a specialized market approach, but the lack of segment data limits the ability to evaluate the performance of individual product lines. The company's growth trajectory is not clearly defined in the provided data, as there are no forward-looking revenue projections or historical growth rates available. The company's current revenue of $5.79 million is likely derived from early-stage product development, partnerships, or grants, rather than commercial sales. The absence of detailed revenue history makes it challenging to assess the company's growth potential. The company's risk assessment indicates a low dilution risk, with no immediate pressure for share issuance. The absence of balance-sheet inputs and going-concern language in source documents suggests that the company may be in a development phase with limited financial disclosures. The company's reliance on external financing could increase the risk of dilution in the future, particularly if clinical trials for its lead product, ADV7103, do not meet regulatory or commercial expectations. Recent events and filings for ADVICENNE S.A. are not detailed in the provided data, but the company's focus on phase III clinical trials for its lead product suggests that regulatory milestones and trial outcomes will be critical near-term events. The company's pipeline includes several niche indications, which may attract partnerships or licensing deals that could impact its financial position.